Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOmar Nadeem, MD
About this trial
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Eligibility criteria
Qualifiers
Previously diagnosed with MM based on standard IMWG criteria
Patient has given voluntary written informed consent before any study-related procedures not part of normal medical care are performed, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
Patient who has been treated with at least 4 prior lines of anti-myeloma treatment including immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
In addition, to at least 4 prior lines of anti-myeloma treatment, patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion
Disqualifiers
Prior exposure to Iberdomide
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy
Known central nervous system involvement.
Trial design
Treatments tested in this trial
- Elotuzumab
- Iberdomide
- Dexamethasone
Treatment groups
49 Participants
are divided into 2 treatment groupsSponsors and collaborators
Omar Nadeem, MD
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Celgene
Collaborator
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov